Dr. Glenn is President of Research and Development and leads Novavax’ discovery, clinical and regulatory teams with responsibility of the RSV programs, including maternal immunization, an RSV F vaccine for older and high risk adults, and a differentiated adjuvanted recombinant seasonal influenza vaccine. He has spent 25 years in the development of vaccines, vaccine delivery and adjuvants. He has led teams in the development of products from concept into late-stage clinical development, including RSV vaccines, Enterotoxigenic E. coli, recombinant adjuvanted seasonal and pandemic vaccines, Ebola, and a vaccine patch. He co-founded IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008. He has co-authored more than 100 peer reviewed publications and abstracts. Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into vaccine development. He completed a Medical Research Fellowship at the Walter Reed Army Institute of Research in Washington, D.C. Dr. Glenn received his Bachelor of Arts degree in Biology and Chemistry from Whitman College and his Doctor of Medicine degree from Oral Roberts University School of Medicine.